NCT Number: NCT00266734
Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears
To compare the efficacy of a recently FDA approved point of care diagnostic test, the RPS Adeno Detector (Rapid Pathogen Screening, Inc.; South Williamsport, PA), against cell culture for detecting adenoviral conjunctivitis
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 month and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
University of Erlangen-Nurnberg, Erlangen, Germany
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinical Study Enrollment Criteria
Upon completing the in-vitro studies, a perspective, blinded clinical study was started. Patients who were older than 1 month of age, seen within 7 days of developing a red eye, and who demonstrate at least one criterion from two out of the three categories below were included:
I. History: 1) Spread from one eye to the other several days later, 2) recent or concurrent upper respiratory symptoms within the preceding two weeks, 3) or an exposure to someone with "pink eye" within the preceding three weeks
II. Symptoms: 1) Tearing, 2) mucoid or purulent discharge, 3) eye lash matting, 4) burning, 5) itching, or 6) foreign body sensation
III. Signs: 1) An inferior palpebral conjunctival reaction with > or = 1+ papillary or follicular reactions, 2) presence of a preauricular node
Exclusion criteria
Patients with associated skin vesicles, corneal dendrites, traumatic corneal abrasion, concurrent corneal ulcers, foreign bodies, ocular pemphigoid, trauma, previous history of chemical/thermal injury to eyes or eyelids (anytime in past), or greater than trace intraocular inflammation were excluded from the study. Additionally, patients with allergy to corn starch, talcum powder, or dacron were also be excluded. Patients using any topical ophthalmic medication (i.e. antibiotics) were required to wait at least 30 minutes from their last dose prior to device application and wait at least 2 hours after their last dose of any ointment application
Treatment and study plan
Primary outcomes
-
Ability to accurately detect presence or absence of adenovirus in conjunctival specimens
Sponsors and collaborators
Lead sponsor
Rapid Pathogen Screening
Industry
Registry information
Official study title
A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis
Important dates
- Study start
- 2004
- Study completion
- 2005
- First posted
- Dec 19, 2005
- Registry last updated
- Feb 11, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Epidemiology of Conjunctivitis in the Emergency Department
NCT03356197
Acute Conjunctivitis
Goiânia, Goiás, Brazil
View Trial DetailsPrevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
NCT04374656
COVID-19, Conjunctival Diseases
Baltimore, Maryland, United States
View Trial DetailsA Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis
NCT00921895
Conjunctival Diseases, Conjunctivitis
Bradenton, Florida, United States
View Trial DetailsReducing Adenoviral Patient Infected Days
NCT02472223
Adenoviral Conjunctivitis, Conjunctival Diseases
St Louis, Missouri, United States
View Trial Details